Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Queissner, R; Lenger, M; Birner, A; Dalkner, N; Fellendorf, F; Bengesser, S; Platzer, M; Hamm, C; Maget, A; Reininghaus, B; Ratzenhofer, M; Schuller, J; Mangge, H; Kapfhammer, HP; Reininghaus, EZ.
The association between anti-inflammatory effects of long-term lithium treatment and illness course in Bipolar Disorder.
J Affect Disord. 2021; 281:228-234 Doi: 10.1016/j.jad.2020.11.063 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Birner Armin
Queissner Robert
Co-Autor*innen der Med Uni Graz
Bengesser Susanne
Dalkner Nina
Fellendorf Frederike
Hamm Carlo
Kapfhammer Hans-Peter
Lenger Melanie
Maget Alexander
Mangge Harald
Platzer Martina
Ratzenhofer Michaela
Reininghaus Bernd
Reininghaus Eva

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

INTRODUCTION: Altered levels of acute-phase proteins are often described in different conditions in BD. Nevertheless, data on the association between lithium treatment and inflammatory markers in the long-term course of BD are still missing. The aim of the study was to examine the long-term course of BD concerning long-term lithium treatment, chronic inflammatory processes and symptom progression. Furthermore, the association between duration of lithium treatment and levels of hsCRP was explored. METHODS: 267 individuals (males= 139, females= 128) with BD were included. Duration of lithium treatment as well as symptom progression, defined as the increase in severity of symptoms, number of episodes a year and duration of episodes within a period of 1.5 years in the past and hsCRP were evaluated. RESULTS: Male individuals with symptom progression over time had significantly lower duration of lithium treatment compared to individuals without symptoms progression (U= 47.4, p=.037). There were significantly higher levels of hsCRP in male individuals with symptom progression compared to males without symptom progression (U= 47.5, p=.027). Further, there was a significant negative correlation between the duration of lithium treatment and hsCRP levels in the whole sample (r= -.276, p<.05). CONCLUSION: Our results show that an altered inflammatory state may be associated with a more severe illness course in BD. Further, a longer duration of lithium treatment may be associated with lower symptom progression. The shown association between hsCRP-levels and lithium treatment duration suggests a potential anti-inflammatory effect of lithium as a mediator of its significant positive outcome effect in BD.
Find related publications in this database (using NLM MeSH Indexing)
Anti-Inflammatory Agents - therapeutic use
Biomarkers - administration & dosage
Bipolar Disorder - drug therapy
Female - administration & dosage
Humans - administration & dosage
Lithium - adverse effects
Lithium Compounds - therapeutic use
Male - administration & dosage

Find related publications in this database (Keywords)
Bipolar disorder
Illness progression
C-reactive Protein
Long-term effects
© Med Uni Graz Impressum